AstraZeneca builds on the fight against rare diseases

Swedish-British pharmaceutical giant AstraZeneca showed with its multibillion USD acquisition of Alexion that it is serious about its push in rare diseases. Now they are following up with another acquisition in the form of the small American biotech company LogicBio. The deal, announced  on Monday, is set to close at $2.07 per share – a premium of a whopping 660 per cent to Friday’s close on the U.S. Nasdaq Stock Exchange.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/astrazeneca-builds-on-the-fight-against-rare-diseases/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se